The case for early deals in med tech (MedDevice)
The time is now for big medical device companies to lift their heads out of their quarterly net earnings reports and start looking seriously at early stage investments in innovation.
To the consternation of many emerging med tech executives and their investors, the big medical device companies are much less active in the early stage deal space than their bio-pharma counterparts. Drug company leadership “gets” that future success depends on robust product pipelines infused with externally sourced innovation at every stage from Discovery clear to ...
